Eligible trials included those evaluating IL-17 or IL-23 inhibitors for PsO and documented PASI scores. Interleukin-17 (IL-17) inhibitors demonstrated faster psoriasis (PsO) clearance than Interleukin ...

Selective interleukin-23 (IL-23) inhibitors for the management of psoriasis are administered every 8 to 12 weeks, compared with previous treatment options that required a weekly, biweekly, or monthly ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Approximately 60% to 85% of patients who develop ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Furthermore, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, TREMFYA® demonstrated clinically meaningful results across all endpoints in both biologic ...

In a retrospective cohort study, treatment with an IL-23 inhibitor was associated with a similar incidence of psoriatic arthritis (PsA) as treatment with IL-2/23 inhibitors in patients with psoriasis.

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Feldman, professor of dermatology, pathology and social ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...